Federal Register / Vol. 72, No. 124 / Thursday, June 28, 2007 / Notices 35501 

supports the effects of the immunotoxin 

against T cells. 

Applications: Use of immunotoxins 

decreases T cell population, allowing 

greater host immune tolerance of 

transplants and grafts; Specific method 

for increasing immune tolerance to 

pancreatic islet transplants. 

Advantages: Specificity of the 

immunotoxin avoids the killing of other 

cells, reducing side-effects associated 

with other mechanisms of treatment (Xray and cyclophosphamide) such as 

infection and induced malignancy; A 

GMP production process for the 

immunotoxin has already been 

successfully implemented. 

Benefits: New methods and 

compositions with limited side-effects 

have the potential to revolutionize 

treatment of transplant/graft recipients; 

provides an opportunity to capture a 

significant market share for the millions 

of people who require transplants/grafts. 

Inventors: David Neville et al. 

(NIMH). 

Patent Status: U.S. Patent No. 

5,167,956 issued 01 Dec 1992 (HHS 

Reference No. E–012–1991/0–US–01); 

U.S. Patent No. 5,762,927 issued 09 Jun 

1998 (HHS Reference No. E–012–1991/ 

4–US–02); U.S. Patent No. 6,103,235 

issued 15 Aug 2000 (HHS Reference No. 

E–012–1991/7–US–01); U.S. Patent No. 

7,125,553 issued 24 Oct 2006 (HHS 

Reference No. E–012–1991/7–US–02); 

U.S. Patent Application No. 09/810,999 

filed 16 Mar 2001, which published as 

U.S. 2001/0024645 on 27 Sep 2001, 

Allowed (HHS Reference No. E–059–

1998/0–US–02); International Patent 

Application No. PCT/US00/10253 filed 

14 Apr 2000, which published as WO 

00/61132 on 19 Oct 2000 (HHS 

Reference E–168–1999/0–PCT–02); U.S. 

Patent No. 6,632,928 issued 14 Oct 2003 

(HHS Reference No. E–044–1997/0–US–

07); U.S. Patent Application No. 10/ 

435,567 filed 09 May 2003, which 

published as 2003/0185825 on 02 Oct 

2003 (HHS Reference No. E–044–1997/ 

0–US–08); U.S. Patent Application No. 

10/296,085 filed 18 Nov 2002, which 

published as 2004/0127682 on 01 Jul 

2004 (HHS Reference No. E–044–1997/ 

1–US–06); Foreign rights are also 

available. 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: David A. 

Lambertson, PhD; 301/435–4632; 

lambertsond@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Mental Health, 

Laboratory of Molecular Biology, is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize 

methods of using the immunotoxins for 

the treatment of rejection response in a 

patient. Please contact David Neville at 

davidn@mail.nih.gov for more 

information. 

Dated: June 20, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–12534 Filed 6–27–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Cancer 

Institute Special Emphasis Panel, 

August 2, 2007, 1:30 p.m. to August 2, 

2007, 3:30 p.m., Marriott Bethesda 

North Hotel & Conference Center, 5701 

Marinelli Road, North Bethesda, MD 

20852 which was published in the 

Federal Register on April 24, 2007, 72 

FR 20348. 

This meeting notice is amended to 

reflect the location change to the 

Embassy Suites Hotel at Chevy Chase 

Pavilion, 1400 Military Road, NW., 

Washington, DC 20015 and meeting 

time to 3 p.m. to 5 p.m. The meeting is 

closed to the public. 

Dated: June 21, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3185 Filed 6–27–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Antibody 

Array for Cancer Detection. 

Date: July 19, 2007. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6116 

Executive Boulevard, Rockville, MD 20852 

(Telephone Conference Call). 

Contact Person: Lalita D. Palekar, PhD, 

Scientific Review Administrator, Special 

Review and Logistics Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., Room 7141, 

Bethesda, MD 20892–7405, 301–496–7575, 

palekarl@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Small 

Grants for Behavioral Research in Cancer 

Control. 

Date: July 26, 2007. 

Time: 8:30 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Courtyard Marriott Gaithersburg 

Washingtonian Ctr., 204 Boardwalk Place, 

Gaithersburg, MD 20878. 

Contact Person: Rhonda J. Moore, PhD, 

Scientific Review Administrator, Special 

Review and Logistics Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 6116 Executive Boulevard, 

Suite 701, Room 7151, Bethesda, MD 20892–

8329, 301–451–9385, moorerh@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Initial Review Group; Subcommittee 

A—Cancer Centers. 

Date: August 2–3, 2007. 

Time: 8 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road, NW., 

Washington, DC 20015. 

Contact Person: Gail J. Bryant, Scientific 

Review Administrator, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., Room 8107, 

MSC 8328, Bethesda, MD 20892–8328, 301–

402–0801, gb30t@nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Lung 

Cancer and Inflammation. 

Date: August 7–8, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, Bethesda, MD 20814. 

Contact Person: Thomas M. Vollberg, PhD, 

Scientific Review Administrator, Special 

Review and Logistics Branch, Division of 

extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., Room 7142, 

Bethesda, MD 20892, 301–594–9582, 

vollert@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

mstockstill on PROD1PC66 with NOTICES